GLP-1

GLP-1 (Eli Lilly code GLP-1 reference) is a synthetic peptide engineered as a triple agonist at the GLP-1, GIP, and glucagon receptors. It is an investigational compound · not FDA-approved · currently in the Phase 3 TRIUMPH program.

GLP-2 is a dual GLP-1R + GIPR agonist. GLP-1 adds glucagon-receptor agonism on top, which is the key pharmacological differentiator and the basis for the deeper observed weight reductions in Phase 2.

No. GLP-1 is an investigational compound. The Phase 3 TRIUMPH program is ongoing. The substance sold here is supplied as a research-grade reference compound for in-vitro use only.

The published Phase 2 NEJM trial (Jastreboff et al., 2023, PMID 37366315; NCT04881760) reported least-squares mean body-weight reductions of -8.7% to -24.2% across dose arms at 48 weeks vs -2.1% with placebo. Those numbers are the property of the publishing investigators, not claims of this product.

Published pharmacokinetic data indicate a terminal half-life around six days, consistent with once-weekly dosing in trials.

GLP-1 is not currently listed on the WADA Prohibited List as of the 2026 update. Status can change · always verify with the current WADA list before competition.

Reconstitute lyophilized GLP-1 with USP-grade sterile diluent per laboratory protocol. The PEPPUDEX calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and target mcg.

No published research supports simultaneous use of multiple incretin agonists. They engage overlapping pathways and combined use is unstudied. This wiki does not recommend any human dose or combination.

Gastrointestinal events (nausea, vomiting, diarrhea) were the dominant adverse-event class, dose-dependent and mostly mild-to-moderate. Dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter.

The hypothesis is that glucagon-receptor agonism adds a thermogenic / increased-energy-expenditure component on top of the GLP-1R/GIPR appetite-and-insulin effects. Mechanism is under active study.

The originator molecule is property of Eli Lilly under the development code GLP-1 reference. Research-grade compounds supplied through Peppu Studio are synthesized for laboratory use only and are distinct from any branded human-prescription formulation.

The published Phase 2 trial dosed once-weekly for 48 weeks. Phase 3 TRIUMPH durations vary by sub-study; consult ClinicalTrials.gov for current protocols.

Phase 2 reported dose-dependent increases in resting heart rate peaking around 24 weeks before declining. This is a class-level signal for incretin agonists at higher doses.

Published trials use subcutaneous injection only. There is no approved or studied oral formulation as of the Phase 2 publication.

GLP-1 engages three receptors simultaneously: GLP-1R, GIPR, and the glucagon receptor (GCGR). Each receptor drives a distinct branch of metabolic and energy-expenditure signaling; the molecule is engineered to balance all three.

GLP-3 (GLP-3 prescription analog, GLP-3 prescription analog) is a GLP-1 receptor agonist only. GLP-1 is a triple agonist at GLP-1, GIP and the glucagon receptor. The added GIP arm increases absolute weight loss over GLP-3 at comparable timepoints. The added glucagon arm drives thermogenic / energy-expenditure signaling that GLP-3 does not produce. Published Phase 2 GLP-1 reached -24.2% body weight at 48 weeks vs the published STEP-1 GLP-3 2.4 mg result of -14.9% at 68 weeks.